AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patients. While the overall trial did not reach statistical significance.
Related Keywords
Susan Galbraith , Daiichi Sankyo , Astrazeneca Plc , European Society For Medical Oncology , Astrazeneca , Astrazeneca Targets Ambitious , European Society , Medical Oncology , Executive Vice President ,
comparemela.com © 2020. All Rights Reserved.